Humana climbs after 2026 Medicare Advantage Star Ratings hold near 3.61 average
Humana shares rose after the company disclosed that about 20% of its Medicare Advantage members are enrolled in plans rated 4 stars or higher for 2026, with its average Star Rating holding at about 3.61. The update eased fears of a sharper quality-driven earnings hit, lifting sentiment across the stock.
1. What’s moving the stock
Humana stock moved higher Monday after investors digested an update indicating roughly 20% of its Medicare Advantage members are enrolled in plans rated 4 stars or above for the 2026 plan year, while the company’s average Star Rating held around 3.61. The data point matters because Star Ratings influence quality bonus payments and rebate levels that can materially affect Medicare Advantage margins and benefit competitiveness.
2. Why the market is reacting now
Humana has been under pressure as investors weighed the earnings drag from prior Star Ratings disruption and elevated medical-cost trends. Today’s gain reflects a relief-style reaction: the disclosure suggests quality performance is stabilizing rather than deteriorating further, reducing the odds of an incremental downside surprise tied to Stars and supporting expectations for a multi-year recovery setup.
3. What to watch next
Investors will focus on whether Humana can convert quality stabilization into improved benefit economics and enrollment momentum heading into upcoming selling seasons, and whether management commentary stays consistent with its 2026 outlook at investor events. The next major swing factors remain medical utilization trends, Medicare Advantage pricing discipline, and any additional CMS policy/rate updates that could reshape 2027 profitability expectations.